Are New Heart Medicines Revealing the Real Culprit? Why Visceral Fat May Be the Missing Link in Heart Disease

Dr Edward Leatham
Dec 12, 2025
4 min read

Updated: Apr 21

An article by Dr Edward Leatham, Consultant Cardiologist

For years, most of us were taught a simple story about heart disease. Keep your cholesterol down, watch your blood pressure, don’t smoke, and stay active. If diabetes isn’t on your list of problems, you’re probably fine.

But in the last few years, something unexpected has happened.

Medicines originally designed for diabetes—SGLT2 inhibitors and GLP-1 receptor agonists—have shown major benefits in protecting the heart. The surprise?

They work even in people who don’t have diabetes.

This finding has forced doctors to look beyond sugar levels and ask a deeper question:

Why do “diabetes drugs” help people without diabetes at all?

The answer, increasingly, points to a powerful metabolic culprit: visceral fat, the hidden fat stored deep around the organs.

What Is Visceral Fat, and Why Does It Matter?

Visceral adipose tissue (VAT) is not the soft fat you can pinch. It’s the internal fat wrapped around the liver, pancreas, gut, and major blood vessels.

This type of fat behaves very differently. VAT:

releases inflammatory chemicals
disrupts the body’s insulin signalling
stresses blood vessels
feeds the metabolic chain reaction behind heart disease

You can have a completely “normal” weight and still have too much VAT. That is why waist measurement is often more revealing than BMI.

When VAT builds up, the risk curve bends sharply upwards.

Why Diabetes Medicines Help People Without Diabetes

1. SGLT2 inhibitors

These tablets prompt the kidneys to pass a small amount of sugar in the urine. The result:

lower insulin levels
lower blood pressure
a shift towards fat-burning
reduced strain on the heart
and a preferential loss of visceral fat

2. GLP-1 receptor agonists

These medicines:

reduce appetite
smooth out glucose spikes after meals
reduce inflammation
improve blood vessel function
help people lose more VAT than normal subcutaneous fat

So the benefits have little to do with having diabetes and everything to do with shrinking the most dangerous fat depot in the body.

A New Understanding of Heart Disease

For decades, heart disease was seen as a plumbing problem: arteries clog, blood flow drops, danger follows.

We now know the story begins much earlier.

VAT creates a metabolic environment that irritates blood vessels from the outside in. It builds silent inflammation, encourages glucose swings, and puts pressure on the heart long before a blockage appears.

Reducing VAT calms the entire system:

inflammation falls
insulin becomes more stable
blood vessels relax
plaques become less vulnerable
blood pressure improves

In this light, it becomes clear why these medicines protect people without diabetes: they are cooling down the metabolic fire that burns beneath the surface.

The Heart–Brain Connection

There is another important piece of this story.

The heart and the brain are metabolic partners. They depend on the same blood supply, the same glucose stability, the same inflammatory balance, and the same metabolic health.

The same hidden forces that stiffen arteries and inflame the heart also affect memory, mood, cognition, and long-term brain resilience.

Which is why modern prevention is beginning to adopt a simple motto:

“What’s good for the heart is good for the brain.”

Everything that lowers visceral fat and smooths out glucose swings supports both organs:

healthy eating patterns
resistance training and muscle building
steady sleep
lower stress
fewer glucose spikes
stable insulin levels
reduced VAT

Protect one, and you lift the other.

Can You Reduce VAT Without Medication?

Yes — and many people do.

VAT responds well to:

moderate calorie reduction
prioritising protein
regular resistance training
short bursts of higher-intensity exercise
avoiding carb-heavy snacks
eating fibre before carbohydrates
tracking your waist size (not just your weight)

GLP-1 receptor agonists and SGLT2 inhibitors are powerful tools, but they work best on a foundation of healthy habits.

The Bottom Line

The new cardiology story is bigger than cholesterol or blockages. It is about metabolism, inflammation, insulin, and the internal fat around our organs.

SGLT2 inhibitors and GLP-1 receptor agonists didn’t just reshape diabetes care — they revealed a deeper truth about heart disease itself:

When you reduce visceral fat, the whole body becomes safer.And the two organs that benefit most are the heart and the brain.

We may be entering a future where understanding your metabolism is just as important as knowing your cholesterol. And that shift has the power to protect your heart, preserve your brain, and change the course of ageing itself.